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Nonspeciﬁc inﬂammation in the transplant microenvironment results in β-cell dysfunction and death inﬂuencing negatively graft
outcome. MicroRNA (miRNA) expression and gene target regulation in transplanted islets are not yet well characterized. We
evaluated the impact of inﬂammation on miRNA expression in transplanted rat islets. Islets exposed in vitro to proinﬂammatory
cytokines and explanted syngeneic islet grafts were evaluated by miRNA arrays. A subset of 26 islet miRNAs was aﬀected by
inﬂammation both in vivo and in vitro. Induction of miRNAs was dependent on NF-κB, a pathway linked with cytokine-mediated
islet cell death. RT-PCR conﬁrmed expression of 8 miRNAs. The association between these miRNAs and mRNA target-predicting
algorithms in genome-wide RNA studies of β-cell inﬂammation identiﬁed 238 potential miRNA gene targets. Several genes were
ontologically associated with regulation of insulin signaling and secretion, diabetes, and islet physiology. One of the most activated
miRNAs was miR-21. Overexpression of miR-21 in insulin-secreting MIN6 cells downregulated endogenous expression of the
tumorsuppressorPdcd4andofPclo,aCa2+ sensorproteininvolvedininsulinsecretion.Bioinformaticsidentiﬁedbothaspotential
targets. The integrated analysis of miRNA and mRNA expression proﬁles revealed potential targets that may identify molecular
targets for therapeutic interventions.
1.Introduction
Inﬂammationinvolves boththeinnateandadaptiveimmune
systems following infection or injury. Deregulation of this
process leads to chronic inﬂammation, generating a patho-
logical response that favors destruction of the tissue involved
[1]. Inﬂammation is the common denominator of several
pathologicalconditions,includingtype1andtype2diabetes.
It also contributes to immune rejection in transplantation.
A plethora of proinﬂammatory mediators has been
associated with toxicity and impairment of β-cell func-
tion [2], including cytokines [3–6], hyperglycemia, and
hyperlipidemia [7–9] .I n ﬂ a m m a t i o np l a y sk e yr o l e si n
islet engraftment and survival after transplantation. During2 Journal of Transplantation
the early posttransplant period, islet cells are exposed to
noxious stimuli, activation of macrophages, local secretion
of chemokines, tissue factor induction, and formation of
reactive oxygen species (ROS) due to hypoxic conditions,
all causing an impairment of engraftment and function
[10–12]. The nonspeciﬁc inﬂammation generated in the
transplant microenvironment triggers adaptive immune
responses, negatively inﬂuencing graft survival [13, 14].
Emerging evidence shows that small noncoding gene
products, miRNAs, negatively regulate gene expression post-
transcriptionally [15, 16]. MiRNAs play a critical role in
inﬂammatory diseases [17–19], in the vascular system [20]
and diabetes [21–25]. In this study, we determined the
expression signatures of miRNAs in islets exposed to proin-
ﬂammatory conditions in vitro [2] or after transplantation.
Locked Nucleic Acids-probe (LNA) MicroRNA hybridiza-
tion arrays and signiﬁcance analysis of microarray (SAM)
identiﬁed miRNA subsets modulated by both experimental
conditions. To identify genes that are directly targeted by
these miRNAs, we performed bioinformatic analysis relating
the miRNA expression proﬁles with genome-wide RNA
(GWR) microarray studies focusing on inﬂammation of
pancreatic β-cells [26, 27].
This approach may lead to the development of molecular
therapies to alter expression of involved miRNAs and their
speciﬁc targets, which may enhance preservation of β-cell
function and survival after transplantation.
2.MaterialandMethods
2.1.IsletIsolation. Animalprocedureswereperformedunder
protocols reviewed and approved by the University of
Miami IACUC. Lewis rats (Harlan, Indianapolis, IN) of
either sex were used as donors and recipients of islet cells.
Islets were obtained by a mechanically enhanced enzymatic
digestion using Liberase (Roche) followed by separation
on discontinuous density gradients (Mediatech) [28]. After
overnight culture at 37◦C, 5% CO2 in supplemented CMRL-
1066 medium (Gibco-Invitrogen), islet aliquots were pre-
pared in non-treated tissue culture dishes for in vitro or
transplantation experiments.
2.2. Islet Exposure to Inﬂammation In Vitro. After over-
night culture, isolated islets were exposed in vitro to a
proinﬂammatory cytokine cocktail [29]. Brieﬂy, recom-
binant human cytokines utilized in combination were
as follows: interleukin-1-beta (IL-1β; 50U/mL), interferon-
gamma (IFN-γ; 100U/mL), and tumor necrosis factor-alpha
(TNF-α; 2,000U/mL), all from R&D Systems. Islets were
exposed to the treatment for 6 and 18 hours. In selected
experiments aimed at dissecting the role of NF-κBp a t h w a y
in cytokine-induced islet miRNA expression, islets were
pretreated for 2 hours with the NF-κB inhibitor Bay11-7082
(5uM), which inactivates IκB-α phosphorylation, and then
cultured with the cytokine cocktail for additional 6 hours.
Untreated islets cultured in parallel were used as controls.
At the end of the incubation period, islets were collected in
saline solution, and then stored in RNALater until processed
for molecular arrays.
2.3. Islet Transplantation and Graft Recovery. Islet aliquots
(∼3,000IEQ each) were transplanted under the kidney cap-
sule, as described [14]. After three days, islet grafts were
collected by careful dissection from the renal subcapsular
space and stored in RNALater for molecular arrays.
2.4. Overexpression of miR-21 in MIN6 Cells. The MIN6
cells were transfected with 200–400nM mimic miR-21
(Dharmacon) or 200–400nM irrelevant control using trans-
fection reagent “Dharmafect” following the manufactures
instructions. Mimic transfected cells and their controls were
cultured 48 hours, harvested and subjected to qRT-PCR.
2.5. LNA-Oligonucleotide-Probes-Based Hybridization Arrays.
RNA was labeled (Hy3 or Hy5 ﬂuorescent dye) using the
miRCURY LNA Array Power labeling kit (Exiqon). The
labeled RNA molecules were hybridized to the miRCURY
LNA Array slides (Exiqon) that contain capture probes for
279ratmicroRNAgenescomplementarytomaturemiRNAs,
registered in miR-Base Release 9.2. After hybridization,
the chips underwent image acquisition (Scanner Axon
model 4100A; Molecular Devices) and the data analyzed
using GenePix Pro 6.0 image analysis software. Replicate
hybridizations of the same control/experimental samples
were performed utilizing the two-color “dye ﬂip reversal
method.” This experiment was repeated with 3 samples for
a total of six hybridizations.
The averages of both hybridizations (Hy3/Hy5 and
Hy5/Hy3) for three samples were analyzed by Signiﬁcant
Analysis of Microarray (SAM). Only miRNAs detected in
both dye ﬂip reversal were included in the analysis. SAM
calculates q-values, a measure of signiﬁcance based on False
Discovery Rate concept for genome-wide association studies
[30]. To increase the stringency of the analysis only samples
with q = 0w e r ec o n s i d e r e d .
2.6. Quantitative RT-PCR. Total RNA was isolated from
transplanted islets using the mirVana miRNA Isolation kit
(Ambion). The isolated RNA can be used for miRNA as well
as mRNA analysis. cDNA synthesis and PCR ampliﬁcation
were performed according to the manufacturer’s protocol
(AppliedBiosystems).MiRNAproﬁlingwasperformedusing
micro-ﬂuidiccardsTaqManLowDensityArray(TLDA,v1.0)
for rodent miRNAs, which allow quantitative assessment
of 365 miRNAs using the AB7900 instrument (Applied
Biosystems). Quantiﬁcation of miR-21 and mRNA was
carried out in a 7500 Fast Real-time PCR system, utilizing
TaqMan reagents (Applied Biosystems) using (RQ) values.
RQrepresentsthefoldchangesofexpressionbetweencontrol
and treated samples, for example, nontransplanted islets
versus transplanted islets. RQs were calculated with the
Applied Biosystems SDS software. The number of ampliﬁ-
cation cycles, Ct, is normalized to endogenous control 18S
rRNA for the TLDA, and beta-actin and snoRNA135 for
mRNA and miR-21 assessments, respectively.
2.7. Semiquantitative RT-PCR Analysis of Pclo Splicing Ver-
sions. PCR was performed using the following primers: PcloJournal of Transplantation 3
forward primer sequence TCCAAGGATATGCAGGTTCC is
shared by both versions (V1 and V2, resp.) and spans
between exons 19 and 20. The reverse primers are speciﬁc
foreachversionandareasfollows:ACGCTATACCCACTGC-
CAAC (V1) and TGAACATTAAGCTGCCATGC (V2).
3. Results
3.1. MicroRNA Expression in Islets after In Vitro Treat-
ment with Proinﬂammatory Cytokines. Inﬂammation can be
mimicked in vitro by exposing islets to proinﬂammatory
cytokines. Speciﬁcally, IL-1β induces functional impairment
and cell death in cultured islets [31], while TNF-α and
IFN-γ enhance cytotoxicity [32]. The miRNA expression
patterns in rat islets exposed to cytokine cocktail [IL-1β
(50U/mL), TNF-α (2000U/mL), and IFN-γ (100U/mL)]
for either 6 or 18 hours (n = 3) were assessed by
LNA-(locked nucleic acids) based microarray analysis, using
Exiqon chips. We chose the LNA probes because of their
accurate sequence discrimination and strong hybridization
[33]. They are comparable to the emergent next-generation
sequencing (NGS) high throughput miRNA proﬁling via
RNA sequencing [34].
The maximum cytokine eﬀect on miRNA proﬁles
occurred 6 hours after treatment, while after 18 hours
the eﬀect was markedly reduced (data not shown). The
results obtained from the miRNA microarrays (n = 3) were
analyzed by SAM [30], adopting a q = 0. Q-values
correspond to the P values adapted to the analysis of a large
number of genes; q = 0 is the minimum false discovery
rate and refers to the chance that a given miRNA is a false
positive (fold changes greater than 2.0). We identiﬁed a pool
of 64 miRNAs (Table 1). The NF-κB pathway has a critical
role in cytokine-induced islet cell death [35]. Therefore, we
investigated if the cytokine-mediated induction of miRNAs
was also dependent on NF-κB activation in our study. Islets
were pretreated for 2 hours with the NF-κB inhibitor Bay 11-
7082 that inactivates IκB-α phosphorylation [36] and then
cultured with the cytokine cocktail. The high throughput
miRNA assay using the Exiqon platform with SAM showed
that blocking of NF-κB pathway caused signiﬁcant reduction
(on average more than 50%, range 24–72%) in the activation
of most miRNAs tested (Table 2).
3.2. Islet miRNA Expression after Transplantation. Islet cells
are exposed to multiple insults after transplantation [37, 38].
To investigate the eﬀect of in vivo inﬂammatory milieu
on the expression of islet miRNAs, we transplanted rat
islets under the kidney capsule of syngeneic recipients, an
experimental model well suited to study early inﬂammatory
events. Since the implanted islets remain in a well deﬁned
mass under the kidney capsule, they can be easily retrieved
with minimal contamination from surrounding tissue for
molecularevaluation[39].Thegraftswereretrieved.MiRNA
expression on islet grafts explanted 3 days after transplant
(n = 3) was analyzed using LNA (Exiqon) microarrays
and subsequent SAM. Nontransplanted islets taken from the
same isolation served as controls. Explanted grafts yielded
a pattern of 31 miRNAs with altered expression: 26 of them
were upregulated and 5 downregulated. PCR-based TaqMan
Low Density Arrays conﬁrmed the expression of 11 miRNAs.
Comparing the miRNA patterns of expression in the in vitro
and in vivo experiments, we retrieved a subset of 26 miRNAs
commonly regulated under both experimental conditions,
24 were upregulated and 2 downregulated (Table 3). Eight
miRNAs from the PCR-conﬁrmed 11 miRNAs, are common
to both in vitro and in vivo inﬂammation conditions; 7
upregulated (miR-21, miR-98, miR-27a, miR-143, let-7d,
miR-126 and miR-22) and one (miR-129) downregulated
(Table 3).
3.3. Inﬂammation-Induced miRNAs and Identiﬁcation of
Their Potential Targets. MiRNAs downregulate their target
mRNA levels causing inhibition of translation [40]. Fur-
thermore, a recent study showed that destabilization of
target mRNAs is the major reason for reduced protein
expression mediated by miRNAs [41]. To identify potential
miRNA targets, we integrated our high throughput miRNA
expression data with previously published transcriptome
studies. We expected that upregulated miRNAs would
correspond to downregulated RNA targets and vice versa.
Speciﬁcally we looked for inverse association between the
expression of islet miRNAs modiﬁed by inﬂammation via
both in vivo and in vitro conditions and the algorithm-
predicted target genes found in a genome-wide mRNA
(GWR) expression studies by Ortis et al. [27]. These authors
studied the modiﬁcation of genes in primary rat β-cells
exposed in vitro to combination of the same cytokines we
used in our study, namely IL-1β+IFN-γ or TNF-α+IFN-γ
[27].
Two of the most commonly used computational miRNA
predictive target programs are miRANDA and PicTar [42–
44]. It has been shown that perfect “seed” pairing is
important for miRNA target recognition and predictability.
The “seed” is the sequence corresponding to nucleotides 2–7
of the miRNA’s 5 region [45]. The predictions by PicTar have
ahigherdegreeofoverlapbecausethesealgorithmsarebased
on stringent “seed” pairing, unlike miRBase that employs
moderate “seed” pairing [46]. It has been reported that
prediction of targets did not improve by using overlapping
algorithms [47]. For that reason, rather than selecting the
common targets to both algorithms, we chose PicTar algo-
rithm to match upregulated miRNAs (miR-21, miR-98, miR-
27a, miR-143, let-7d, miR-126, miR-22) with downregulated
putative targets in Ortis et al. and vice versa (Table 4).
The PicTar algorithm identiﬁed 202 downregulated mRNAs
which according to Ortis’ study are potential targets for
either of the above-mentioned upregulated miRNAs, and
36 upregulated mRNAs the possible targets for downreg-
ulated miR-129 (Table 4). From the 202 downregulated
genes, 108 are targeted by one miRNA, and the rest are
targeted by multiple miRNAs (data not shown). Interest-
ingly, 30 genes are associated with regulation of insulin
signal transduction pathways, development, and function
of pancreatic islets, insulin secretion, and insulin resistance
(Table 4).4 Journal of Transplantation
Table 1: miRNAs expressed in islets treated in vitro with a cocktail of IL-1β,I F N - γ,a n dT N F - α were identiﬁed by SAM of global miRNAs.
The score (d) represents value of the T-statistic; a higher score means a greater diﬀerence between the two groups. q-values correspond to
the P values adapted to the analysis of a large number of genes. FI and SD are fold increase and standard deviation of hybridization values
(cytokine versus control), respectively.
Upregulated miRNAs (d) q (%) FI SD miRNA (d) q (%) FI SD
miR-143 6.7 0 7.5 3.5 miR-27a 4.5 0 6.2 4.2
miR-30e 6.0 0 15.3 11.4 let-7a 4.4 0 8.4 7.1
miR-182 6.0 0 9.1 4.8 miR-375 4.4 0 7.8 6.4
miR-96 6.0 0 13.6 9.4 miR-30a 4.4 0 5.3 3.3
miR-141 5.9 0 13.2 10.6 miR-19b 4.3 0 6.6 4.5
miR-24 5.7 0 9.2 6.2 let-7f 4.3 0 19.8 25.4
miR-29b 5.5 0 12.7 11.2 miR-16 4.1 0 4.7 2.9
miR-212 5.5 0 9.8 7.0 miR-29c 4.1 0 10.6 10.2
miR-7a 5.2 0 10.7 8.6 miR-103 4.1 0 3.0 0.9
miR-19a 5.2 0 3.9 1.3 miR-148b-3p 4.0 0 7.1 6.1
let-7i 5.2 0 13.7 9.6 miR-30d 3.9 0 4.1 2.3
miR-153 5.1 0 25.0 27.8 miR-301a 3.9 0 22.3 26.5
miR-22 5.1 0 4.7 1.9 let-7c 3.9 0 5.1 3.5
miR-27b 5.0 0 8.1 5.7 miR-23b 3.8 0 4.3 2.5
miR-21 5.0 0 10.2 6.5 miR-29a 3.7 0 5.8 4.5
miR-30b-5p 5.0 0 6.6 4.2 miR-23a 3.6 0 4.3 2.6
let-7d 4.9 0 9.6 7.7 miR-204 3.6 0 7.4 8.2
miR-30c 4.8 0 6.5 4.0 miR-541 2.9 0 13.1 16.0
miR-200a 4.8 0 13.0 11.5 miR-99b 2.9 0 13.1 1.3
miR-207 4.8 0 4.6 2.2 rno-let-7b 2.8 0 3.6 2.3
miR-183 4.8 0 4.7 2.0 miR-125b-5p 2.7 0 3.0 1.7
miR-127 4.8 0 7.6 3.8 miR-17/17-5p 2.7 0 9.9 14.2
miR-107 4.7 0 6.0 3.7 miR-194 2.5 0 2.9 1.8
miR-335 4.7 0 2.8 0.7 miR-200c 2.4 0 2.6 1.4
miR-101a 4.7 0 3.9 2.7 miR-125a-5p 2.4 0 2.6 1.5
miR-26a 4.7 0 6.5 4.5 miR-200b 2.3 0 2.7 1.5
miR-98 4.6 0 9.3 7.8 miR-340-5p 2.2 0 2.3 1.1
miR-7b 4.6 0 14.0 13.4 let-7e 2.0 0 2.3 1.1
miR-126 4.5 0 4.5 2.2 miR-337 2.0 0 2.0 2.3
miR-106b 4.5 0 4.0 1.5
Downregulated miRNAs (d) q (%) FI SD
miR-185 −2.8 0 4.0 3.3
miR-129 −3.0 0 2.8 1.5
miR-503 −3.2 0 4.1 3.2
miR-370 −3.4 0 3.5 2.1
miR-206 −4.3 0 2.6 0.7
3.4. Regulation of Endogenous mRNA by miR-21. To further
test whether some of these 30 genes (Table 4)c o u l db e
associated functionally with speciﬁc miRNAs, we studied
selected miRNA overexpression eﬀect on putative endoge-
nous mRNA targets in the mouse insulin-secreting cell line
MIN6. Since miR-21 was identiﬁed as the most reproducibly
induced miRNA in vitro and in vivo, with the highest
score “d” in SAM analysis (Table 3), we focused on this
miRNA. Programmed cell death 4(Pdcd4) and Piccolo
(Pclo) are miR-21 potential targets (Table 4). Pdcd4 is a
tumor suppressor gene that inhibits neoplastic transfor-
mation, tumor progression, and translation. It has been
identiﬁed as miR-21 target in several systems [84]. Pclo is
a high molecular weight (550kDa), multidomain protein
functioning as a scaﬀold for proteins involved in synaptic
vesicle endo- and exocytosis near their site of action. Pclo
is proposed to function as Ca2+ sensor protein in cAMP
insulin secretion in islets [50]. In vitro treatment of MIN6
cells with cytokines induced the expression of miR-21
(Figure 1(a)). Overexpression of miR-21 achieved by the
addition of a mimic miR-21, but not of an irrelevant mimic
miRNA (control), decreased the expression of both Pdcd4
and Pclo mRNAs in MIN6 cells (Figure 1(b)). It has been
described that Pclo consists of two major splicing versions:Journal of Transplantation 5
Table 2: miRNAs selected by SAM analysis of global miRNA
expression in islets exposed in vitro to cytokines with or without
inhibition of the NF-κB pathway. Values are expressed as percentage
ofvalues obtained withNF-κBinhibitorBay11-7082pluscytokines
versus cytokines alone.
miRNA CTK+Bay miRNA CTK+Bay
versus CTK (%) versus CTK (%)
miR-206 72.8 miR-143 33.70
miR-17/17-5p 61.8 miR-24 33.71
miR-541 59.1 miR-370 33.71
miR-101a 57.6 miR-96 33.28
miR-503 54.0 miR-125a-5p 32.87
miR-106b 52.5 miR-200a 32.82
miR-194 51.0 miR-16 32.79
miR-204 50.9 miR-99b 32.70
miR-148b-3p 49.6 miR-26a 32.44
miR-19a 48.3 miR-200c 32.43
miR-19b 46.2 miR-337 32.39
miR-129 45.9 miR-30c 32.12
miR-301a 41.4 miR-7a 32.03
miR-30d 40.6 miR-23a 31.92
miR-127 40.2 miR-27a 31.91
miR-335 39.4 miR-30b-5p 31.81
rno-let-7f 39.4 miR-200b 31.67
miR-183 38.5 miR-125b-5p 31.63
miR-212 38.4 miR-375 30.78
rno-let-7e 37.7 rno-let-7b 30.71
miR-22 36.9 miR-27b 30.63
miR-29a 36.3 rno-let-7d 30.60
miR-98 36.1 rno-let-7c 30.57
miR-23b 35.8 rno-let-7a 30.31
miR-185 35.7 miR-153 29.32
miR-182 35.3 miR-30e 29.21
miR-207 35.3 miR-141 29.20
miR-340-5p 35.3 miR-29b 28.11
miR-107 34.8 miR-30a 27.84
miR-126 34.3 rno-let-7i 27.65
miR-7b 33.9 miR-21 25.75
miR-103 33.8 miR-29c 24.66
V1 and V2 [85]. Their biological role is not currently
known. Only V2 has an miR-21 recognition site in its
3 UTR. The miR-21: Pclo interaction site has a mismatch
in the “seed” region; however, it displays a more extensive
base pairing at the 3  end of the miRNA (Figure 1(c)).
Semiquantitative PCR analysis showed that Pclo V2 is pre-
dominant in MIN6 cells (Figure 1(d)). Therefore, we could
conﬁrm the speciﬁcity of miR-21 to induce downregulation
of endogenous Pclo in β-cells. These results suggest that
in pancreatic islets miR-21 targets both Pdcd4 and Pclo
genes.
4. Discussion
Islets of Langerhans are highly vascularized endocrine cell
clusters located in the pancreas. The islet isolation process
utilizes fragmentation of the gland to free the islets from
the surrounding tissue, which results in a loss of vascular
support. Consequently, the islets undergo hypoxic stress that
persistsuntilfullrevascularizationintherecipient’smicroen-
v i r o n m e n ti sc o m p l e t e d ,w h i c hm a yl a s ts e v e r a lw e e k s[ 86].
Multiple factors, such as the duration of organ ischemia
and the islet isolation process, contribute to activation of
stress-induced signal transduction pathways and generation
of inﬂammation mediators by islet cells [28]. Thus, islet cells
participate actively in the initiation of local inﬂammation,
which is further triggered by the transplant procedure.
These responses may further amplify adaptive immunity
responses after transplantation resulting in impairment of
β-cell function and viability. Modulation of inﬂammatory
responses in the early peritransplant period is associated
with improved islet engraftment and function in both
experimental and clinical settings. The purpose of our study
was to identify islet microRNAs modulated in vitro and in
vivoby inﬂammatory events. In the clinical settings, the islets
are implanted into the hepatic portal system where they are
exposed to blood, ischemia and activation of endothelium
all contributing to the inﬂammatory reaction elicited in
the transplant microenvironment. Unfortunately, it would
be quite cumbersome to retrieve the graft from the liver
for molecular analysis without introducing important biases
(i.e., enzymatic digestion and puriﬁcation to collect the islets
otherwise randomly distributed into the liver parenchyma).
Conversely, despite lacking key features of the intrahepatic
site, the kidney subcapsular space allows the easy retrieval
of the grafted tissue for molecular analysis with minimal
manipulation.
The molecular pathways involved in islet cell response to
inﬂammation during the peritransplant period are yet to be
fully understood. Transcriptome analysis of explanted islet
grafts has revealed a key involvement of NF-κB pathway as
an initial adaptation response to the new microenvironment
and the underlying tissue remodeling during the peritrans-
plant period [87].
The emerging role of miRNAs as master regulators
of gene expression has opened new avenues toward the
thorough understanding of cellular responses under various
physiological and pathological conditions. Indeed, herein
we report that miRNAs expression is regulated by the
inﬂammatory milieu generated in transplanted islets. We
have identiﬁed a pool of 26 miRNAs commonly aﬀected
by inﬂammation both in vivo and in vitro, suggesting their
association with the intrinsic basic molecular mechanism
determining the fate of islet grafts in the early posttransplant
period.
Our study includes an integrated evaluation of miRNAs
and mRNAs gene expression in insulin secreting cells along
with functional studies identifying new targets for miR-
NAs activated by proinﬂammatory cytokines. Induction of
miRNA transcription was partially dependent on activation
of NF-κB, a transcription factor with a critical role in6 Journal of Transplantation
Table 3: SAM of miRNAs expressed in transplanted syngeneic islets collected 3 days after implantation. MiRNA expression in transplanted
islets was compared to control isolated islets. 26 common miRNAs that displayed altered expression in vivo and in vitro (cytokine treated
islets) are shown in bold font. MiRNA conﬁrmed by PCR are marked with an X in the last column. FI and SD are fold increase and standard
deviation of hybridization values (transplanted islets versus control islets), respectively.
Upregulated miRNAs (d) q-(%) FI SD PCR
miR-21 7.75 0.00 26.58 13.21 X
miR-98 4.40 0.00 7.94 3.60 X
miR-212 4.33 0.00 51.61 43.25
miR-27a 4.15 0.00 19.56 14.07 X
rno-let-7i 4.13 0.00 16.16 15.27
miR-207 4.01 0.00 20.62 15.18
miR-143 3.94 0.00 9.12 6.07 X
rno-let-7a 3.89 0.00 13.03 9.55
rno-let-7d 3.89 0.00 7.20 3.30 X
miR-126 3.83 0.00 41.18 60.44 X
miR-195 3.68 0.00 8.12 5.00 X
miR-22 3.66 0.00 10.14 8.45 X
miR-27b 3.54 0.00 10.57 6.85
miR-107 3.49 0.00 8.16 5.90
miR-99b 3.38 0.00 5.01 2.15
miR-214 3.34 0.00 10.52 7.15 X
miR-125b-5p 3.33 0.00 8.13 4.95
rno-let-7e 3.20 0.00 3.76 1.37
miR-23a 3.17 0.00 9.24 8.21
rno-let-7b 2.95 0.00 5.27 3.79
miR-24 2.93 0.00 7.61 6.34
miR-30e 2.91 0.00 7.77 4.92
miR-23b 2.87 0.00 7.37 6.20
miR-26a 2.80 0.00 5.93 3.69
miR-29c 2.77 0.00 6.97 4.10
miR-375 2.74 0.00 6.04 3.89
Downregulated miRNAs (d) q-(%) FI SD PCR
miR-542-5p −6.03 0.00 19.82 11.24
miR-129 −5.09 0.00 25.58 25.01 X
miR-326 −3.03 0.00 5.89 4.12 X
miR-370 −2.85 0.00 4.78 1.87
miR-484 −2.55 0.00 11.70 2.74
β-cell apoptosis mediated by proinﬂammatory cytokines
(Table 2)[ 35, 88]. The convergence of miRNAs and NFκB
signaling pathway has been recently established [89]. Using
quantitative PCR-based high throughput analysis, we have
conﬁrmed upregulation of 7 (miR-21, miR-98, miR-27a,
miR-143, let-7d, miR-126, and miR-22) and downregulation
of 1 (miR-129) miRNAs out of the 26 activated miRNAs
identiﬁed in our settings. The relatively low number of
miRNAs conﬁrmed by RT-PCR in our study might be due
to the low reproducibility of miRNA proﬁling interplatforms
[90].ThismayalsoexplainwhymiRNAspreviouslyreported
in islets upon in vitro cytokine exposure, such as miR-
146 and miR-34a, were not conﬁrmed in our study [25].
Some of the 8 miRNAs have been reported previously in
studies related to islet physiology or diabetes. MiR-21 has
a potential role in diabetic nephropathy [91]. Low plasma
levels of miR-21 and miR-126 have been detected in patients
with type 2 diabetes [92]. In agreement with our results,
cytokines increased miR-21 expression in β-cells, while
miR-21 downregulation conferred cytoprotection to islets
exposed to IL-1β in vitro [25]. The expression patterns of
miR-27a varied with hyperglycemia in the Gyoto-Kakizaki
rat [5], and miRNA-143 overexpression inhibited insulin-
stimulated AKT activation and resulted in impaired glucose
metabolism [93].
Our results suggest that overexpression of miR-21 in
MIN6 cells could regulate the expression of Pdcd4 and
Pclo steady-state mRNA levels. The tumor suppressor
proinﬂammatory protein Pdcd4 promotes activation of the
transcription factor NF-κB[ 94]. Downregulation of Pdcd4Journal of Transplantation 7
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Figure 1: Overexpression of miR-21 regulates endogenous Pdcd4 and Pclo mRNAs. (a) MIN6 cells were treated 24 hours with cytokine
cocktail IL-1β (50U/mL), TNF-α (2000U/mL), and IFNγ (100U/mL). The expression of miR-21 was assessed by qRT-PCR. (b)
Overexpression of miR-21 mimic (300nM) for 48hs inhibits the expression of endogenous Pdcd4 and Pclo mRNA. Experiments shown
in (a) and (b) are expressed as mean±SD (n = 5), ∗P<0.05 (t-test, 2 tails). (c) miR-21 recognition site in the 3 UTR of Pclo splicing
version 2. MiR-21 “seed” is shown in red font. (d) Semiquantitative RT-PCR shows expression of both Pclo versions (V1, V2) in MIN6
insulinoma cells.
by miR-21 has been associated with attenuation of cytotoxic
eﬀects of oxidative stress and ischemia-reperfusion in car-
diomyocytes[95,96],decreasingtheproinﬂammatoryeﬀects
of TLR4 signaling [94], and also preventing type 1 diabetes
in rodents [49]. Furthermore, miR-21 targets the Pclo gene
w h i c ha c t sa saC a 2+ sensor via formation of a cAMP-
GEFII(Epac2)-Rim2 complex in PKA-independent cAMP
insulin secretion. Pclo inhibition impairs cAMP insulin
secretion [50]. Therefore, miR-21 has the ability to regulate
g e n e ss u c ha sP c l oa n dP d c d 4t h a tm i g h ta ﬀect β-cells
in conﬂicting manner. On one hand, during inﬂammation
miR-21 contributes to the impairment of islet cells function
by interfering with insulin exocytosis via downregulation of
Pclo. On the other hand, miR-21 could reduce cytokine-
mediated apoptosis in β-cells via downregulation of Pdcd4.
Divergent eﬀects have been also reported in islets treated
with cytokines for mRNAs, such as STAT1 and IRF-1
[97].
Collectively, our study and the results of previous reports
regarding the eﬀect of cytokines on gene expression in islet
β-cells [25–27, 98] indicate that proinﬂammatory cytokines
trigger a complex response resulting in modulation of the
expression of islet mRNAs and miRNAs, which in some cases
might aﬀect the system in a seemingly contradictory fashion.
In the context of transplantation, it is likely that the ﬁnal
outcome of the cytokine eﬀect on islet cells depends on the
combination of factors, such as intensity and duration of
exposure, and initial quality of the islet graft (i.e., viability).
In conclusion, we found a set of miRNAs that are
regulated by inﬂammatory conditions in transplanted islets.
In addition, the theoretical bioinformatics analysis identiﬁed
potential genes that are directly regulated by these miRNAs.
This information could be helpful for future studies of novel
genes involved in inﬂammation-mediated β-cells dysfunc-
tion as well as for the development of new therapeutic
applications.
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